New haemophilia drug has been approved, however it costs $3.5m per dose

Introducing the new IPT website: www.IPTonline.com

FDA approvals to WISE for neuromonitoring device

Introducing the new IPT website: www.IPTonline.com

This issue covers topics from the vaccine industry to follicular lymphoma, and all the latest news

The editor introduces this issue of Pharmafocus

Samedan Ltd

NHS and MHRA approve new prostate cancer treatment

The RCN has voted for more strikes throughout December

A world-first trial is expected to evaluate the efficacy of stem cell transplants for MS patients

Cabometyx receives NICE recommendation

The team behind the Oxford-AstraZeneca COVID-19 vaccine have turned to malaria

Upstaza given marketing authorisation for AADC deficiency

AstraZeneca has announced that three of its drugs have been recommended for EU approval. The three drugs are: Imfinzi, Enhertu and Lynparza, all of which can be used to treat different cancers.

Karyopharm Therapeutics and the Menarini Group’s Nexpovio (selinexor) has been granted orphan medicinal product designation by the European Commission (EC). The drug is intended to treat myelofibrosis (MF), a rare kind of bone marrow cancer.

Polish clinical stage biotechnology company Molecure has announced its third quarter results for the period ending 30 September 2022. Its press release also mentions its plans for its R&D day in December, and its strategies and preparations for various phase 1 and 2 clinical trials.

A few weeks ago, the FDA warned of an amoxicillin shortage that may affect paediatric patients in the US; that shortage has now come to a head amid emergency room waiting times of up to 15 hours in some US hospitals. Many pharmacies across the country are also reportedly struggling to keep up with demand for the drug.

AstraZeneca and MSD have launched a prostate cancer awareness campaign

The FDA has announced that it is aiming to make opioid overdose medications available without prescriptions.

Merck has donated ebola vaccines to be tested on a resistant strain of the virus

Eisai and Biogen's new Alzheimer's drug, lecanemab, appears to slow disease progression but remains controversial.

Pulmonx, a US-based medical technology company, has secured approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Zephyr Endobronchial Valve, used to treat patients with severe chronic obstructive pulmonary disease (COPD) or emphysema.

Amgen Inc’s new obesity drug has appeared promising in its small phase 1 trial, meaning it will be able to go ahead with a larger mid-stage trial in 2023. The trial demonstrated that patients were able to maintain their weight loss for 70 days following the highest dose of the drug, known as AMG133.

Ryvu Therapeutics, a clinical-stage oncology therapeutics development company, has announced a collaboration with BioNTech, which will consist of two parts: multi-target research into several small molecule immunotherapy programmes and an exclusive licence agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.

Promising results announced from human trial of new HIV vaccine

Simiens Healthineers and Atrium Health announce partnership deal

AstraZeneca announces acquisition of Neogene

Focus-X Therapeutics develops targeted radiopharmaceuticals to treat cancer, based on proprietary peptide engineering technology. This technology involves peptide radioliglands which precisely deliver alpha or beta emitters to break down cancer cell DNA. It allows for high-quality optimisation of peptide radioligland vectors for key pharmaceutical attributes such as biodistribution, binding affinity, and in vivo stability.

Lupin Healthcare have launched a carbon-neutral inhaler for adult asthma patients

Parthenon Therapeutics, a precision oncology company that is focusing on inventing a novel class of anti-cancer therapies to reprogramme the tumour microenvironment (TME), is collaborating with ImaginAb Inc, a global biotechnology company developing imaging agents and radiopharmaceutical therapies (RPT) products.

The FDA has removed approval for Eli Lilly's bebtelovimab due to its decreasing efficacy

Eli Lilly lost billions in stock following tweets from a fake but verified account on twitter

Elon Musk's Neuralink announces that human trials are planned for its brain chip in 2023

Novo Nordisk's connected pens are now compatible with Abbott's FreeStyle LibreLink app

Why do such a significant amount of vaccines in the UK come from Flanders and what does this mean in the ongoing COVID-19 pandemic?

PharmaRole - Coming Soon!

The Follicular Lymphoma Foundation tells Pharmafocus about new research being conducted into blood cancer follicular lymphoma and their new research grant programme

FlyPharma Middle East 2023

Scott Curley appointed general manager at Amarin

Dr Frank Mathias appointed to CEO of Oxford Biomedica

Peter Williams is appointed to general manager at Incyte Biosciences UK

Five facts about vaccines from the first vaccine to WHO's estimations of vaccine efficacy

Pharmatimes - International Clinical Researcher of the Year - entry deadline is approaching fast